LEXINGTON, Mass.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ:AGEN) reported results today for the quarter ended June 30, 2009. The company incurred a net loss attributable to common stockholders of $12.3 million, or $0.17 per share, basic and diluted, for the second quarter of 2009, compared with a net loss attributable to common stockholders of $12.5 million, or $0.19 per share, basic and diluted, in the second quarter of 2008. For the six months ended June 30, 2009, the company incurred a net loss attributable to common stockholders of $22.0 million, or $0.31 per share, basic and diluted, compared with a net loss attributable to common stockholders of $24.0 million, or $0.40 per share, basic and diluted, for the comparable period in 2008. The company’s net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the three months ended June 30, 2009 and 2008 was $5.7 million and $6.9 million, respectively. The company’s net cash burn for the six months ended June 30, 2009 and 2008 was $15.5 million and $16.3 million, respectively. The 2009 results reflect the company’s efforts to support Oncophage in Russia, Europe, and other territories, while also executing cost containment efforts. Cash, cash equivalents, and short-term investments were $21.1 million as of June 30, 2009.
